Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:07:36.543Z.
Calculation as of: 2026-10-06T15:07:36.543Z.
Quote observation: 2026-10-06T15:02:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1ca0602d484fef860d1886a06048f849113dfee726f77a026e2ec96edb2346c6
PE RATIO
N/A
Market Cap
$82.69M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MediciNova, Inc. (MNOV) | $83.18M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.43M | N/A | 3.67 | 3.67 | 3.67 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.69M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $82.66M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.66M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.58M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $85.04M | N/A | 8.03 | 8.03 | 8.03 |
| Citius Oncology, Inc. (CTOR)vs › | $80.89M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $85.53M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $80.12M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.69
Forward EPS (Est.)
$-0.25
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
